Enuresis

ICD-10F98.0	Nonorganic enuresis
DSM-5-TRF98.0	Enuresis

1. Definition and nosology

Enuresis (ICD-11: 6C00; DSM-5-TR: F98.0) — voluntary or involuntary urination persisting when the child’s developmental age reaches at least 5 years. Frequency: at least twice a week for ≥ 3 months or significant functional impairment.

Subtypes (ICCS — International Children’s Continence Society 2014):

1. Monosymptomatic nocturnal enuresis — only nocturnal, no daytime symptoms;
2. Non-monosymptomatic enuresis — daytime symptoms (urgency, increased frequency, incontinence) additional;
3. Primary — child has never achieved 6 months of sustained dryness;
4. Secondary — relapse after a dry period.

2. History

• In the 19th century, familial clustering of enuresis began to be noted in the clinical literature.
• Mowrer O.H. (1938) — invented the pad-and-bell alarm.
• ICCS (1989) — international standardization.
• NICE CG111 (2010) — nocturnal enuresis clinical guideline.

3. Epidemiology

• Prevalence: Age 5: 5–10%, Age 10: 3–5%, ≥ 15 years: approximately 1% (DSM-5-TR).
• Sex: male 2:1.
• Spontaneous remission occurs in approximately 15% per year.
• Comorbidity: ADHD ~30%, anxiety, conduct disorders, constipation.

4. Etiology and pathogenesis

• Heritability approximately 70% (twin and family studies).
• Monosymptomatic nocturnal enuresis — pathogenesis:
  • Immaturity of nocturnal vasopressin (ADH) secretion (nocturnal polyuria);
  • Elevation of arousal threshold;
  • Bladder capacity below age norm.
• Non-monosymptomatic form — bladder overactivity, association with constipation.
• Secondary enuresis — stress, urinary infection (UTI), diabetes, psychiatric trigger.

5. Clinical features

• Nocturnal enuresis.
• Daytime symptoms (non-monosymptomatic): urgency, holding maneuvers (Vincent’s curtsy, leg crossing), increased frequency, incontinence.
• Social-emotional: shame, decreased self-esteem, avoidance of social activities (camping, sleepovers).

6. Diagnosis

6.1 Unified diagnostic criteria (DSM-5-TR / ICD-11 / ICCS 2014)

A. Repeated urinary incontinence (in bed or clothes), voluntary or involuntary.

B. Frequency: ≥2 times per week, ≥3 months; or significant distress/functional impairment.

C. Developmental age ≥ 5 years.

D. Not explained by a substance (diuretic) or medical condition (diabetes, UTI, structural anomaly).

Qualifiers: only nocturnal / only diurnal / nocturnal and diurnal; primary / secondary; monosymptomatic / non-monosymptomatic.

6.2 Differences between sources

• ICCS 2014 — subtype terminology standard.
• NICE CG111 — diagnosis and algorithm.
• AAP — pediatric assessment.

6.3 Diagnostic algorithm

• Clinical interview — onset, frequency, daytime symptoms, family history.
• Urinalysis and culture — rule out UTI.
• Voiding diary 3 days — for daytime symptoms.
• Constipation assessment (Bristol Stool Chart).
• Medical: weight, glucose, blood pressure.
• If structural anomaly suspected — urinary ultrasound; uroflowmetry in non-monosymptomatic case.

6.4 Differential diagnosis

7. Examination and assessment

1. Urine analysis, culture.
2. Voiding and constipation diary.
3. Urinary ultrasound (atypical presentation).
4. Comorbid ADHD, anxiety screening.

8. Treatment

8.1 General principles (ICCS 2020 · NICE CG111)

• Behavioral intervention:
  1. Conservative recommendations — reducing fluid intake before bedtime, adequate water intake during the day, regular urination, resolving constipation.
  2. Positive reinforcement (star chart) — for dry nights.
• First-line specific intervention:
  • Enuresis alarm — pad-and-bell; ≥ 6 years old, if motivated; long-term good outcome; about 50% achieve 14 consecutive dry nights and about 40% remain dry at follow-up (low-quality evidence). Evidence: Caldwell P.H. Cochrane 2020.
  • Desmopressin — synthetic ADH analog; rapid effect, but high relapse upon discontinuation. Age ≥ 6–7 years.
• Second-line:
  • Alarm + desmopressin combination;
  • Anticholinergic (oxybutynin) — in the context of non-monosymptomatic overactive bladder.
• Refractory: imipramine (TCA) — cardiac monitoring; use with caution because of the risk of overdose toxicity.
• Resolving constipation — PEG (polyethylene glycol) first-line; in non-monosymptomatic or comorbid encopresis context.

8.2 Treatment methods

• Enuresis Alarm — Mowrer — Bed alarm or clothing alarm (humidity sensor); ≥ 4 weeks continuous use; typical use 12–16 weeks. Cochrane meta-analysis — most evidence-based long-term method.
• Desmopressin — Oral 0.2–0.4 mg or sublingual melt 120–240 µg; 1 hour before bedtime; limiting fluids before bedtime is important (risk of hyponatremia).
• Voiding and Constipation Diary — 3-day; frequency, volume, bladder capacity, daytime symptoms, defecation frequency.
• Anticholinergic (Oxybutynin) — Against a background of overactive bladder; if daytime symptoms are present.
• PEG (Constipation correction) — First-line; also used in encopresis.

8.3 Differences between sources

1. ICCS 2020 — alarm and desmopressin first-line; “wait and see” until age 5, then active intervention.
2. NICE CG111 — same algorithm.
3. AAP — pediatric recommendations.

9. Prognosis

• Spontaneous remission occurs in approximately 15% per year; with intervention, remission occurs in most patients.
• Constipation management is important.
• Comorbid ADHD, anxiety — parallel intervention.

10. Myths and misconceptions

Myth 1: “In nocturnal enuresis, iontophoresis (drug electrophoresis) to the groin and buttock area stimulates the urinary center”

Why it is widespread: Soviet-era physiotherapy practice; presented as “safe” by family doctors.

Clinical logic: If daytime urine output is normal and the problem did not spontaneously arise after any illness, the problem is not at the kidney/bladder/spinal cord level. Pathogenesis is ADH dysregulation, arousal threshold and bladder capacity — electrophoresis does not affect these.

Evidence: ICCS 2020, NICE CG111 — no international guideline includes electrophoresis. Risk: skin irritation, psychosexual burden.

Real clinical step: Alarm or desmopressin.

Myth 2: “It will just pass on its own, no intervention needed”

Evidence: Spontaneous remission ~15% per year, but untreated persistence creates social-emotional burden; ICCS 2020 recommends active intervention from age 5+.

Myth 3: “Punishment or insult corrects a child”

Evidence: Punishment is contraindicated; self-esteem reduction, depression risk; positive reinforcement is superior.

Myth 4: “Pre-bedtime water restriction alone is sufficient”

Evidence: Adjunct measure; ineffective alone in most patients; requires specific intervention.

Myth 5: “Imipramine or antidepressants are first-line”

Evidence: imipramine in refractory cases; cardiac side effects and overdose risk; alarm and desmopressin are superior to it.

Myth 6: “Acupuncture and homeopathy cure enuresis”

Evidence: Cochrane reviews — the effect of these complementary interventions has not been proven.

11. Sources

• WHO. ICD-11. 6C00 Enuresis. 2024.
• APA. DSM-5-TR. 2022.
• NICE CG111. Nocturnal enuresis in children and young people under 19. 2010.
• Nevéus T. et al. Management and treatment of nocturnal enuresis — an updated standardization document from the International Children’s Continence Society. J Pediatr Urol 2020;16(1):10–19.
• Caldwell P.H., Codarini M., Stewart F. et al. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2020;(5):CD002911.
• Bayoumi R.A., Eapen V., Al-Yahyaee S. et al. The genetic basis of inherited primary nocturnal enuresis: a UAE study. J Psychosom Res 2006;61(3):317–320.